

Joseph R. Berger
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 3

- 48. (New)The composition of claim 44 for sublingual administration.--
- 49. (New)The composition of claim 44 for transdermal administration.--
- 50. (New)The composition of claim 44 for oral administration.--
- 51. (New)The composition of claim 44 for administration over a time period in the range of about 2 weeks to about 6 months.--
- 52. (New)The composition of claim 51 wherein the effective amount provides a daily dosage in the range of about 2.5 to about 30 milligrams oxandrolone.--
- 53. (New)The composition of claim 52 wherein the effective amount provides a daily dosage of about 7.5 milligrams oxandrolone.--
- 54. (New)The composition of claim 52 wherein the effective amount provides a daily dosage of about 15 milligrams oxandrolone.--
- 55. (New)The composition of claim 52 wherein the effective amount provides a unit dose of about 1 to about 5 milligrams oxandrolone and is administered 3 times per day at about equally spaced intervals.--

Joseph R. Berger
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 4

--56. (New) A composition according to claim 52 comprising oxandrolone for the amelioration of myopathy and muscle weakness in a patient infected with a Type-1 human immunodeficiency virus and a pharmaceutically acceptable carrier such that the composition is an oral composition and is appropriate for administration for a time period in the range of about 2 weeks to about 6 months.--

--57. (New) The composition of claim 56 in the form of a tablet.--

--58. (New) A composition for the amelioration of myopathy and muscle weakness comprising oxandrolone in an amount effective to attenuate the rate of muscle mass loss in a patient infected with a Type-I human immunodeficiency virus.--

REMARKS

The subject application is a continuation of U.S. Serial No. 09/469,817 filed December 22, 1999. An Official Notice of Allowance was issued on August 24, 2001 in connection with U.S. Serial No. 09/469,817. The Notice of Allowance indicated that the Issue Fee was due on November 26, 2001. The Issue Fee was paid in a timely manner, but U.S. Serial No. 09/469,817 has not yet issued as a U.S. patent as of the filing of the subject application. Accordingly, U.S. Serial No. 09/469,817 is pending and the subject application is co-pending therewith for purposes